Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term ...

BridgeBio's launch of Attruby in the U.S. is off to a strong start. Read how this successful effort puts the biotech in a ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target hoisted by Scotiabank from $49.00 to $52.00 in a research ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

BridgeBio Pharma (BBIO) announces $500M convertible notes offering to repay debt, reduce interest expenses, and boost flexibility.

Investing.com -- Shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) dipped 3% in after-hours trading on Monday following the company's announcement of a proposed offering of convertible senior notes to ...

BridgeBio beat investor expectations with 1,028 unique prescriptions for ATTR-CM therapy Attruby, setting the company up to ...

State of New Jersey Common Pension Fund D raised its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 21.6% ...

The Senate voted to confirm Kash Patel as FBI Director. NBC News' Sahil Kapur reports from Capitol Hill. Brendan Buck, former ...

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...